To include your compound in the COVID-19 Resource Center, submit it here.

Soliris eculizumab regulatory update

The U.K.'s NICE issued draft guidance recommending Alexion's Soliris eculizumab to treat atypical hemolytic uremic syndrome (aHUS), but the recommendation is contingent in part on measures ultimately aimed at reducing the drug's impact on NHS's budget. NICE estimates Soliris will

Read the full 403 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE